Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Scientists Image Peptide-Binding GPCR Activity for First Time

Researchers at the National Institutes of Health say they used atomic level images to show how the neuropeptide hormone neurotensin might activate its receptors. Their description reportedly is the first of its kind for a neuropeptide-binding G protein-coupled

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Researchers at the National Institutes of Health say they used atomic level images to show how the neuropeptide hormone neurotensin might activate its receptors. Their description reportedly is the first of its kind for a neuropeptide-binding G protein-coupled receptor (GPCR), a class of molecules involved in a wide range of disorders and the target of many drugs.

“G protein-coupled receptors are found throughout the body. Knowing how they work should help scientists devise better treatments,” said Reinhard Grisshammer, Ph.D., an investigator at the National Institute of Neurological Disorders and Stroke and the senior author of the study (“Structural prerequisites for G-protein activation by the neurotensin receptor”), which is published in Nature Communications.

Neurotensin is thought to be involved in Parkinson's disease, schizophrenia, temperature regulation, pain, and cancer cell growth. Previously, Dr. Grisshammer and his colleagues showed how neurotensin binds to the part of its receptor located on a cell's surface. In the current, they demonstrated how binding changes the structure of the rest of the receptor, which passes through a cell's membrane and into its interior. There neurotensin receptors activate G proteins, a group of molecules inside cells that controls a series of chemical chain reactions.

For these experiments, scientists shot X-rays at crystallized neurotensin receptor molecules. Making crystals of receptors that activate G proteins is difficult. In most studies, scientists have investigated inactive receptors.

“The receptor we crystallized is very close to the active form found in nature,” said Dr. Grisshammer. “We may have the first picture of a peptide-binding G protein-coupled receptor just before it engages with the G protein.”

To achieve their results, the scientists made multiple genetic modifications to a less active version of the neurotensin receptor they had used before. Experiments performed in test tubes showed that mixing the receptor with neurotensin sparked the G protein reactions for which the scientists were looking.

When the scientists looked at the structure of the new crystals, they discovered how binding of neurotensin to the receptor caused critical parts of the receptor located below a cell's surface to change shape. In particular, they saw that a region in the middle of the receptor dropped like a draw bridge to link the neurotensin binding site to parts of the receptor found inside cells that are important for G protein activation. The scientists concluded that this change may prepare the receptor for activating G proteins.

“For years scientists have made educated guesses about how peptide receptors work. Now we may finally know,” said Dr. Grisshammer.

His lab plans to continue its work in order to fully understand how neurotensin and other G protein-coupled receptors translate messages delivered by neuropeptides into reactions inside cells.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01So, how can this definition challenge be overcome?

To precisely define self and non-self peptides and, in turn, self-similarity, we must first improve our understanding of the adaptive immune cascade and its constituent components. In brief, the fundamental unit of adaptive immune recognition comprises the major histocompatibility complex (MHC) molecules (called the human leukocyte antigen [HLA] in humans), the peptide being presented (and, in turn, identified as self or non-self), and the T cell receptor.

Source: www.news-medical.net ↗
02What was this study about?

It has been noted in around 20 percent of the world population suffers from some form of pain or the other. In many individuals, pain may be relieved initially with pain medications, but soon tolerance develops, and there is a decrease in the efficacy of pain relievers. One of the main symptoms of IBS seen commonly in many sufferers is chronic abdominal pain. Professor Lewis said, "All pains are complex, but gut pain is particularly challenging to treat and affects around 20 percent of the world's population. Current drugs are failing to produce effective pain relief in many patients before side effects limit the dose that can be administered." Professor Brierley echoed this statement saying, "Internal organs have a complex network of sensory nerves that have a wide array of voltage-gated ion channels and receptors to detect stimuli... The hypersensitivity of these nerves in disease often contributes to the development of pain."

Source: www.news-medical.net ↗
03What was done in this study?

In the study, published in Scientific Reports, the researchers built on their earlier discovery of the peptide called AC253. This compound was tested in mice with AD. It was found to block the attachment of beta-amyloid to a brain cell receptor called the amylin receptor, and thus inhibit its toxic effects, as shown by an improvement in spatial memory. However, it is difficult to administer this compound because it doesn’t cross the blood-brain barrier in large amounts, and is quickly broken down in the blood. The dosage must therefore be massively increased, pushing up the amounts required for efficacy and increasing the difficulty of administration, besides enhancing the chances of an immune reaction. One way out is to convert the formulation into a pill rather than an injectable form. The complex structure of AC253 makes this difficult as well. Instead, the team devised an ingenious solution. They cleaved the compound into smaller amylin peptides, or chains of 12-14 amino acids, and tested each for its anti-amyloid activity in old mice which showed signs of AD. In this way, they found two short peptides that had the same effects as the larger compound. In particular, the researchers identified a segment that was common to both peptides, namely, SQELHRLQTY.

Source: www.news-medical.net ↗
04What roles does the system play?

The endogenous opioids and their receptors are widely distributed throughout the central and peripheral nervous systems, particularly the parts of these systems that regulate pain, emotion, reward, stress responses, motivation, drug addiction, and autonomic control. The differential expression and location of the various receptor subtypes across different neurons account for the wide range of opioid-related behaviors. The activation of µ-opioid receptors is mainly known for playing a role in pain relief. Still, research has also indicated it may be involved in behaviors related to survival, such as appetite and reproduction. The activity of µ-opioid receptors is also known to play a critical role in responses to social stimuli by modulating responses to social rejection or social acceptance, for example. Activation of the δ-opioid receptors and κ-opioid receptors is also known to be involved in pain modulation. Also, studies have shown that NOP activation is involved in pain mechanisms and several behaviors related to psychological stress. Alterations in the endogenous opioid system are suspected to be involved in Parkinson's disease, seizures, neuroprotective mechanisms, and depression.

Source: www.news-medical.net ↗
05What is nisin?

Some bacterial species produce antimicrobial peptides known as bacteriocins that have been used in the food industry as preservatives. For example, nisin, which is produced by Lactococcus lactis, has broad-spectrum bactericidal activity and has been used as a food preservative throughout the world. Nisin is effective in controlling Gram-positive bacteria such as Clostridioides difficile. In combination with other compounds like ethylene diamine tetra-acetic acid and cinnamaldehyde, nisin has been effective in controlling enterotoxigenic Gram-negative bacteria such as Escherichia coli. Previous studies have used chicken and mouse models to demonstrate the in vivo efficacy of nisin on the microbiome, whereas nisin efficacy has been proven in ex vivo experiments on the human microbiome. To date, no studies have assessed the in vivo effects of nisin in large mammals.

Source: www.news-medical.net ↗
comparison

Comparisons

Side-by-side pages for commonly compared peptides and research compounds.

Source: peptideuniv.com
Research context

Read sources and limitations before applying a claim.

Longevity, Performance & Obesity Research

A research peptide formulation developed to investigate metabolic regulation, mitochondrial function, and nutrient-sensing pathways.

Source: mypeptidematch.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →